CANY
AVIR icon

Caxton Associates (New York)’s Atea Pharmaceuticals AVIR Stock Holding History

Caxton Associates (New York)’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,998
Closed -$56.9K – 496
2023
Q1 		$56.9K Buy
+16,998
New +$69K 0.01% 473

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caxton Associates (New York)'s AVIR Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 16,998 shares — an estimated $56.9K sold.

Caxton Associates (New York) first reported a position in AVIR in Q1 2023 and held it in 1 quarter. The position peaked at $56.9K in Q1 2023. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 16,998 Atea Pharmaceuticals shares in Q2 2023, an estimated $56.9K.
  • Caxton Associates (New York) first reported a position in Atea Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Caxton Associates (New York)'s Atea Pharmaceuticals position peaked at $56.9K in Q1 2023.
  • 133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.